# A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants

> **NCT01900652** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 111 (actual)

## Conditions studied

- Carcinoma, Non-Small-Cell Lung

## Interventions

- **DRUG:** Emibetuzumab
- **DRUG:** Erlotinib

## Key facts

- **NCT ID:** NCT01900652
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-08
- **Primary completion:** 2015-02
- **Final completion:** 2016-03
- **Target enrollment:** 111 (ACTUAL)
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01900652

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01900652, "A Study of Emibetuzumab in Non Small Cell Lung Cancer (NSCLC) Participants". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01900652. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*